Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • NPI Medicare & Medicaid
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.28
    OpenPayerPolicy UpdatesPain ManagementAmbetter Nevada Nerve Blocks Coverage Update | Ope…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentAmbetter NevadaPolicy CP.MP.170

    Nerve Blocks and Neurolysis for Pain Management

    Customize your policy alerts

    Sign up for Ambetter Nevada Policy CP.MP.170 alerts

    Get alerted when Policy CP.MP.170 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity, coverage criteria, and limitations for a range of peripheral and sympathetic nerve blocks and neurolysis procedures for non‑Medicare Ambetter Nevada members, including diagnostic and therapeutic uses and indications where treatment is not supported.

    Policy Summary
    PayerAmbetter Nevada
    PolicyNerve Blocks and Neurolysis for Pain Management
    Policy CodePolicy CP.MP.170
    Change TypeNo material changes
    Effective Date
    Next Review Date
    Key ActionObtain prior authorization and document prior conservative therapy and response to diagnostic injections to support medical necessity.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ≤1procedure limit per visit
    ≤4occipital injections /12 mo
    ≥3wsympathetic conservative trial
    ≥3mceliac repeat interval
    insufficientbasivertebral evidence

    Coverage Criteria for Peripheral and Sympathetic Nerve Procedures

    inv-01: Occipital Nerve Block — Diagnostic

    Covered when ALL of the following are met:

    Occipital diagnostic: Initial injection is medically necessary when: 1) patient has unilateral or bilateral pain located in the distribution of the greater, lesser and/or third occipital nerves; 2) pain has at least two of the following characteristics: recurring paroxysmal attacks, severe intensity, or shooting/stabbing/sharp quality; 3) pain is associated with dysesthesia and/or allodynia on innocuous stimulation of the scalp and/or hair, and at least one of: tenderness over the affected nerve branches or trigger point at the emergence of the greater occipital nerve or in the distribution of C2.

    inv-02: Occipital Nerve Block — Therapeutic

    Covered when ALL of the following are met:

    Occipital therapeutic: Therapeutic occipital nerve blocks are medically necessary when: 1) there was temporary relief from the initial/previous injection as evidenced by reduction in numeric rating scale pain score; 2) the member has failed three months of conservative treatment including: heat/rest/physical therapy (including massage); NSAIDs unless contraindicated; oral anticonvulsants (e.g., carbamazepine, gabapentin, pregabalin) or tricyclic antidepressants; and activity modification to address triggers; 3) no more than four injections are given within 12 months (includes diagnostic injection).
    Policy Summary
    PayerAmbetter Nevada
    PolicyNerve Blocks and Neurolysis for Pain Management
    Policy CodePolicy CP.MP.170
    Change TypeNo material changes
    Effective Date
    Next Review Date
    Key ActionObtain prior authorization and document prior conservative therapy and response to diagnostic injections to support medical necessity.
    SourceLink
    On This Page
    Coverage Criteria for Peripheral and Sympathetic Nerve ProceduresProcedure and Reference CodesProvider Requirements, Authorization, and DocumentationRequired Conservative Care Before Interventional ProceduresProcedure Frequency and Interval LimitsImaging Guidance and Procedural Imaging RecommendationsProcedures and Indications Considered Not Medically NecessaryBackground and RationaleDefinitions
    no more than 4 injections per 12 months

    inv-04: Celiac Plexus Nerve Block/Neurolysis

    Covered when ANY of the following specific indications are met:

    Pancreatic cancer indication: Chronic neuralgic pain secondary to pancreatic cancer when: a) diagnosis of pancreatic cancer with severe visceral abdominal or back pain; b) strong analgesics (opioids) are no longer effective or their side effects decrease quality of life; c) no malignancy in an area of somatic innervation such as the peritoneum or diaphragm.
    Chronic pancreatitis indication: Refractory pain due to chronic pancreatitis with a non-dilated pancreatic duct.

    inv-05: Celiac Plexus Repeat Criteria

    Covered when ALL of the following are met:

    Celiac repeat for chronic pancreatitis: Repeat celiac plexus nerve block for refractory pain from chronic pancreatitis with nondilated pancreatic duct is medically necessary when: 1) at least three months have passed since the previous injection; and 2) there was clinical benefit from the initial celiac block (e.g., alleviation or reduction of abdominal pain or elimination of need for oral analgesia).>=3 months since prior injection

    inv-06: Intercostal Nerve Block/Neurolysis

    Covered when ALL of the following are met:

    Intercostal nerve block/neurolysis is medically necessary for chronic neuralgic pain secondary to an injured intercostal nerve (e.g., rib fracture, thoracotomy incision) or chronic post-herpetic neuralgia or other neuropathic process when: 1) a suspected organic problem exists; 2) non-responsiveness to conservative modalities of treatment; 3) pain and disability are of moderate to severe degree; and 4) no contraindications such as infection or predominantly psychogenic pain.

    inv-07: Peripheral/Ganglion Nerve Blocks

    Covered when ALL of the following specific indications are met:

    Malignant pain: Peripheral nerve blocks for diagnosis and treatment of malignant pain are medically necessary as part of a comprehensive pain management program.
    Post-herniorrhaphy diagnostic: A first diagnostic peripheral nerve block for post-herniorrhaphy neuralgia is medically necessary when: 1) diagnosis of post-herniorrhaphy neuralgia; 2) groin pain has persisted for three months after surgical hernia repair; 3) less invasive pain management methods (NSAIDs and/or opiates) have not relieved the pain; 4) imaging studies have ruled out non-neuropathic causes; and 5) documentation indicates pain is not attributable to any other cause.>=3 months since repair
    Post-herniorrhaphy therapeutic: Therapeutic peripheral nerve block(s) for post-herniorrhaphy pain are medically necessary when: 1) there was temporary relief from the initial/previous injection; and 2) injections are given at least one week apart.>=1 week between injections

    inv-08: Neurolysis / Celiac Plexus Blocks

    Covered when clinical criteria are met for the specific indications below:

    Celiac plexus neurolysis for pancreatic cancer: Celiac plexus neurolysis for pain associated with advanced pancreatic cancer is supported by evidence demonstrating reduced opioid use and pain; pooled pain relief with EUS-guided neurolysis is reported at approximately 53–80%, though optimal timing is uncertain and repeat neurolysis is effective in only about 30% of cases and is not recommended.
    Celiac plexus block for chronic pancreatitis: Celiac plexus blockade is an option for refractory pain in chronic pancreatitis with a non-dilated pancreatic duct; pain relief is typically transient (approximately 3–6 months) and the American College of Gastroenterology gives a conditional recommendation based on very low quality evidence.

    inv-09: Intercostal and Thoracic Blocks

    Covered when clinical criteria are met for thoracic/intercostal indications:

    Intercostal nerve blocks for chest/upper abdominal pain: Intercostal nerve blocks may be used for chest and upper abdominal pain (e.g., rib fractures, post-herpetic neuralgia). Initial management for isolated injuries is NSAIDs with or without opioids; blocks are indicated for more severe injuries (e.g., compromised ventilation) or when multiple rib fractures require multiple levels. Repeated blockade may be needed for prolonged relief when prior response demonstrated by improved physical and functional status.

    inv-10: Peripheral/Ganglion Nerve Blocks

    Covered as part of multimodal management when clinical indications met:

    Genicular nerve procedures and peripheral blocks for focal pain: Genicular nerve blocks and radiofrequency neurotomy are emerging with limited and conflicting evidence; peripheral nerve blocks are used for surgical anesthesia, postoperative analgesia, chronic focal pain, and cancer-related pain as part of a comprehensive multimodal program. Optimal candidates have focal pain of shorter duration, appropriate expectations, and managed psychosocial distress.
    Post-herniorrhaphy groin pain management: For post-herniorrhaphy groin pain, suspect neuralgia after 6–8 weeks; imaging should exclude non-neuropathic causes and patients with positive response to an initial nerve block may receive repeat blocks every 1–3 weeks until sustained relief is achieved.repeat every 1-3 weeks if initial positive response

    inv-11: Basivertebral Nerve Ablation

    Covered when ALL of the following are met:

    Basivertebral nerve ablation (Intracept): Intended for chronic low back pain of at least six months' duration that has not responded to at least six months of conservative care, and with MRI findings consistent with Type 1 or Type 2 Modic changes. The device (Intracept) is FDA-cleared; evidence is limited and guideline support is mixed.>= 6 months conservative care

    Occipital nerve block for the diagnosis or treatment of other headache types, including migraine and cervicogenic headaches, is considered not medically necessary because effectiveness has not been established.

    Sympathetic nerve blocks for any indication other than the specified CRPS criteria (for example, ischemic limb pain) are considered not medically necessary due to lack of evidence supporting effectiveness.

    Peripheral nerve blocks used for the prevention or treatment of headaches (including migraine and similar primary headache syndromes) are considered not medically necessary because current evidence is limited and effectiveness has not been established.

    Genicular nerve blocks, neurolysis, and genicular radiofrequency neurotomy, as well as intraosseous radiofrequency ablation of the basivertebral nerve, have insufficient evidence to determine safety and effectiveness; available studies are limited and conflicting, and these procedures are not supported as standard therapy at this time.

    Inclusion or exclusion of procedure codes in the coding tables is informational only and does not by itself guarantee coverage or payment; providers must follow current coding guidance and payer authorization requirements when submitting claims.

    Coverage determinations under this policy are subject to the terms, conditions, exclusions, and limitations of the member's coverage documents. When state Medicaid provisions conflict with this policy, state Medicaid provisions take precedence.

    Additional sympathetic nerve blocks beyond the first or second are not medically necessary when there is no documented benefit from the initial blocks; repeat blocks should only be considered if given at least one week apart and there was an immediate positive response to the prior block(s).

    Peripheral nerve blocks for the prevention or treatment of headaches (including migraine) are considered not medically necessary because evidence supporting their use for headache prevention or treatment is limited and inconclusive.

    Genicular nerve procedures and intraosseous radiofrequency ablation of the basivertebral nerve are considered to have insufficient evidence for safety and effectiveness and therefore are not supported as established treatments based on current peer‑reviewed literature.

    Policy history and revision notes document prior changes in indications (for example, reclassification of ischemic leg pain to not medically necessary); consult the full policy history and current criteria for complete context when reviewing prior decisions.

    Procedure and Reference Codes

    Covered CPT Codes (injection procedures)CPTCovered
    64400Injection(s), anesthetic agent(s) and/or steroid; trigeminal nerve, each branch (ie, ophthalmic, maxillary, mandibular).
    64405Injection(s), anesthetic agent(s) and/or steroid; greater occipital nerve.
    64408Injection(s), anesthetic agent(s) and/or steroid; vagus nerve.
    64415Injection(s), anesthetic agent(s) and/or steroid; brachial plexus, including imaging guidance, when performed.
    64417Injection(s), anesthetic agent(s) and/or steroid; axillary nerve, including imaging guidance, when performed.
    64418Injection(s), anesthetic agent(s) and/or steroid; suprascapular nerve.
    64420Injection(s), anesthetic agent(s) and/or steroid; intercostal nerve, single level.
    64421Injection(s), anesthetic agent(s) and/or steroid; intercostal nerve, each additional level.
    64425Injection(s), anesthetic agent(s) and/or steroid; ilioinguinal, iliohypogastric nerves.
    64430Injection(s), anesthetic agent(s) and/or steroid; pudendal nerve.
    1–10 of 14
    1/2
    Covered CPT Codes (neurolysis/ablation)CPTCovered
    64454Injection(s), anesthetic agent(s) and/or steroid; genicular nerve branches, including imaging guidance, when performed.
    64505Injection, anesthetic agent; sphenopalatine ganglion.
    64510Injection, anesthetic agent; stellate ganglion (cervical sympathetic).
    64517Injection, anesthetic agent; superior hypogastric plexus.
    64520Injection, anesthetic agent; lumbar or thoracic (paravertebral sympathetic).
    64530Injection, anesthetic agent; celiac plexus, with or without radiologic monitoring.
    64600Destruction by neurolytic agent, trigeminal nerve; supraorbital, infraorbital, mental, or inferior alveolar branch.
    64605Destruction by neurolytic agent, trigeminal nerve; second and third division branches at foramen ovale.
    64610Destruction by neurolytic agent, trigeminal nerve; second and third division branches at foramen ovale under radiologic monitoring.
    64620Destruction by neurolytic agent, intercostal nerve.
    1–10 of 16
    1/2
    Referenced Medicare LCD/LCA identifiersmixed
    L36850Local coverage determination: peripheral nerve blocks
    L39420Local coverage determination: thermal destruction of the intraosseous basivertebral nerve (BVN)
    A57788Local coverage article: peripheral nerve blocks
    L33933Local coverage determination: peripheral nerve blocks
    FDA 510(k) referencemixed
    K190504FDA 510(k) Premarket Notification for Intracept Intraosseous Nerve Ablation System (reference PDF ID)
    inv-26: Duration of conservative care before basivertebral nerve ablation — required duration
    Required duration of conservative care>= 6 months of conservative care prior to basivertebral nerve ablation
    Clinical imaging requirementMRI findings consistent with Type 1 or Type 2 Modic changes required to support procedure
    Indication durationChronic low back pain of at least 6 months duration

    Provider Requirements, Authorization, and Documentation

    Prior Authorization

    Prior Authorization and Procedure Limits

    Invasive pain management procedures are limited to one procedure per visit; prior authorization may be required by the Health Plan. Providers should verify prior authorization requirements with the member’s specific plan and follow applicable Health Plan administrative policies and Medicare guidance where relevant.

    • One invasive procedure per visit policy applies to non‑Medicare plans affiliated with Centene.
    • Prior authorization requirements vary by plan — check member benefits and Health Plan administrative rules before scheduling.
    Billing Rule

    Coding Inclusion Is Not a Guarantee of Coverage

    Inclusion of CPT or other procedure codes in this clinical policy does not guarantee coverage or payment. Providers must confirm current coding guidance and billing rules and ensure services are consistent with the member’s contract, applicable exclusions, and limitations.

    • Coding in this policy is informational only; verify coding edits, bundling rules, and modifier requirements prior to claim submission.
    • Coverage is subject to the member’s evidence of coverage/certificate of insurance and to state and federal requirements.
    Documentation Required

    Occipital Block Documentation

    For occipital nerve blocks, document that the initial or prior diagnostic/therapeutic injection produced temporary relief — for example, a patient‑reported reduction in numeric rating scale (NRS) pain score. Also document failed conservative therapy as required (see conservative therapy callout).

    • Record pre‑ and post‑injection pain scores (e.g., NRS) to demonstrate temporary relief from the diagnostic injection.
    • Document the clinical rationale linking relief from the injection to the targeted occipital nerve distribution.
    Documentation Required

    Documentation of Medical Necessity

    Providers should document that services meet the clinical criteria in this policy and any applicable coverage documents. Documentation must support medical necessity and include diagnosis, prior conservative therapies, response to prior injections when applicable, timing intervals between injections, and objective findings when relevant.

    • Include diagnosis, relevant history, and clinical findings (e.g., tenderness, allodynia, temperature changes).
    • Detail prior conservative treatments tried and their duration, and document objective/subjective response to prior nerve blocks.
    • If repeating blocks, document benefit from the initial block and adherence to required interval thresholds (e.g., ≥3 months for repeat celiac plexus for chronic pancreatitis; ≥1 week between sympathetic or peripheral therapeutic blocks as specified).
    Step Therapy

    Conservative Therapy Requirement

    Therapeutic nerve blocks (including occipital and sympathetic blocks where indicated) require documentation of failure of specified conservative treatments prior to approval. Conservative therapy components vary by indication and must be present in the medical record.

    • Occipital nerve block: failed ≥3 months of conservative treatment including heat/rest/physical therapy, NSAIDs (unless contraindicated), oral anticonvulsant or tricyclic antidepressant therapy, and activity modification.
    • Sympathetic nerve block for CRPS: failed ≥3 weeks of conservative therapies (activity modification, exercise, topical agents, oral medical management) and participation in active rehabilitation.
    • Peripheral post‑herniorrhaphy blocks: trial of less invasive measures such as NSAIDs and/or opioids and imaging to exclude non‑neuropathic causes prior to diagnostic block.

    Required Conservative Care Before Interventional Procedures

    inv-47: Documented failure of specified conservative therapy prior to therapeutic block — occipital 3 months; sympathetic >=3 weeks

    Covered when ALL of the following conservative therapy documentation requirements are met prior to approval of a therapeutic nerve block:

    Occipital therapeutic conservative requirement: For therapeutic occipital nerve block: documented failure of three months of conservative therapy including heat/rest/physical therapy (including massage), NSAIDs (unless contraindicated), oral anticonvulsants or tricyclic antidepressants, and activity modification.Occipital: >= 3 months
    Sympathetic (CRPS) conservative requirement: For sympathetic nerve blocks for CRPS: documented failure of at least three weeks of conservative therapies such as activity modification, exercises, topical lidocaine or capsaicin, and oral medical management (NSAIDs, antidepressants, anticonvulsants, glucocorticoids).Sympathetic: >= 3 weeks
    General conservative therapies expectation: Providers are expected to follow generally accepted standards of medical practice and evidence-based guidelines prior to interventional procedures, and document prior conservative care per those standards.

    inv-48: Document prior conservative care for >=6 months — baseline requirement for some procedures (e.g., basivertebral ablation)

    Covered when ALL of the following are met:

    Basivertebral conservative documentation: Basivertebral nerve ablation candidates must have documented prior conservative care for at least six months without adequate improvement before consideration for the procedure.>= 6 months prior conservative care

    Procedure Frequency and Interval Limits

    inv-50: Occipital nerve injections — maximum of four injections
    Maximum number of occipital injectionsNo more than four injections within 12 months (includes diagnostic injection)
    Documentation for therapeutic useTherapeutic use requires temporary relief from prior injection and failure of 3 months conservative therapy
    Conservative therapy componentsHeat/rest/physical therapy, NSAIDs unless contraindicated, oral anticonvulsants or TCAs, activity modification
    inv-51: Additional sympathetic nerve blocks — when considered, blocks given at least one week apart
    Minimum interval between sympathetic blocksBlocks must be given at least one week apart
    Response required to consider additional blocksImmediate positive response to first or second block (e.g., improved temperature >=1.5°C and decreased pain)
    Denial conditionAdditional sympathetic blocks without documented benefit from first or second are not medically necessary
    inv-52: Celiac plexus block for chronic pancreatitis — repeat allowed after 3 months
    Minimum interval for repeat celiac plexus block (chronic pancreatitis)>= 3 months since previous injection
    Clinical benefit requirement for repeatThere must have been clinical benefit from the initial celiac block (e.g., alleviation/reduction of abdominal pain or elimination of need for oral analgesia)
    Indication for initial procedureRefractory pain due to chronic pancreatitis with non-dilated pancreatic duct
    inv-53: Celiac plexus neurolysis — repeat effectiveness ~30%; repeat not routinely recommended
    Effectiveness of repeat neurolysisRepeat celiac plexus neurolysis effective only about 30% of the time
    Recommendation on routine repeatsRepeat neurolysis is not recommended due to limited effectiveness
    Pooled pain relief for initial EUS-guided neurolysisPooled pain relief reported at 53–80% for pancreatic cancer patients
    inv-54: Groin nerve blocks/post-herniorrhaphy blocks — repeat every 1–3 weeks if initial positive response
    Repeat interval for groin/post-herniorrhaphy blocksCan be repeated every 1–3 weeks if initial positive response
    Initial diagnostic timingPost-herniorrhaphy neuralgia suspected if pain persists beyond 6–8 weeks; positive initial block may guide therapy
    Imaging requirementPatients should undergo imaging to exclude non-neuropathic causes before nerve block interventions

    Imaging Guidance and Procedural Imaging Recommendations

    Note

    Imaging optional for invasive pain procedures

    Imaging for invasive pain management procedures is optional and procedures may be performed with or without radiographic guidance per clinician judgment.

    • Policy states procedures are medically necessary when criteria met, with or without radiographic guidance
    • One procedure allowed per visit
    Note

    Use imaging guidance when clinically indicated for specified procedures

    Use imaging guidance as clinically indicated for intercostal blocks, genicular procedures, basivertebral ablation, and peripheral blocks; many CPT descriptions include imaging guidance when performed.

    • Ultrasound may reduce complications for intercostal blocks
    • CPT descriptions for genicular, basivertebral, and other codes reference imaging guidance
    Note

    Follow referenced LCA/LCD and procedural imaging standards

    Adhere to procedural and imaging guidance referenced in the policy and in applicable Medicare Local Coverage Determinations and coverage articles when performing peripheral nerve procedures and intraosseous ablation.

    • References and LCD/LCAs imply adherence to procedural standards
    • Review CMS Local Coverage Articles and Determinations as applicable

    Procedures and Indications Considered Not Medically Necessary

    Not covered examples include: occipital nerve block for migraine or cervicogenic headache, sympathetic nerve blocks for ischemic limb pain and other unsupported indications, and peripheral nerve blocks for prevention or treatment of headaches; these are listed because effectiveness has not been established for these uses.

    Additional not‑covered statements clarify that repeat sympathetic blocks without benefit will be denied and that coding tables do not ensure coverage — providers should verify authorization requirements and document clinical benefit when seeking additional procedures.

    Peripheral nerve blocks for trigeminal neuralgia and for prevention or treatment of headaches (including migraine) lack sufficient evidence and are considered investigational or not medically necessary for these indications.

    Genicular nerve blocks, neurolysis, genicular radiofrequency neurotomy, and intraosseous basivertebral nerve RFA are considered unsupported due to insufficient published evidence and are therefore not covered for routine treatment of chronic pain conditions.

    Evidence for peripheral nerve blocks in headache disorders is limited to small series and inconsistent findings; larger, controlled studies are necessary before these indications can be supported as covered therapies.

    Background and Rationale

    Nerve blocks temporarily interrupt peripheral nerve conduction by injecting local anesthetic and can serve diagnostic or therapeutic roles; specific indications and limitations vary by block type and the available evidence.

    Definitions

    inv-42: Definition — Nerve block
    DefinitionTemporary interruption of conduction of impulses in peripheral nerves or nerve trunks by injection of local anesthetic solutions
    UsesCan be diagnostic to identify pain source or therapeutic to treat pain
    MechanismLocal anesthetic injection interrupts peripheral nerve conduction temporarily
    inv-51: Definition — Occipital neuralgia
    DefinitionOccipital neuralgia: unilateral or bilateral paroxysmal, shooting or stabbing pain in the posterior scalp in distribution of greater, lesser, or third occipital nerves
    Associated findingsMay be accompanied by diminished sensation or dysesthesia and commonly tenderness over involved nerve(s)
    Diagnostic criterionRelief of pain following local anesthetic block is part of IHS diagnostic criteria for occipital neuralgia
    inv-52: Definition — Genicular nerve block / radiofrequency neurotomy
    DefinitionProcedures targeting sensory genicular nerves around the knee to address joint pain (genicular nerve block, neurolysis, radiofrequency neurotomy)
    Evidence statusEmerging interventions with limited and conflicting evidence for predictive value and efficacy
    Clinical useMay be considered for knee pain, but further research needed to establish safety and efficacy
    inv-53: Definition — Basivertebral nerve ablation (Intracept)
    DefinitionThermal intraosseous radiofrequency ablation of the basivertebral nerve intended to treat chronic low back pain associated with vertebral endplate (Modic) changes
    Indication summaryFor chronic low back pain ≥6 months not responsive to ≥6 months conservative care with MRI features consistent with Type 1 or Type 2 Modic changes
    Evidence summaryCurrent studies report pain relief and functional improvement but are mostly company-sponsored and of limited quality; guideline support is weak and mixed
    inv-54: Definition — Intracept intraosseous nerve ablation system (FDA 510k)
    Device regulatory statusIntracept Intraosseous Nerve Ablation System is FDA 510(k)-cleared for intraosseous basivertebral nerve ablation
    ManufacturerRelievant Medsystems, Inc. (Intracept system components: RF probe, access instruments, RF generator)
    Intended vertebral levelsIntended for ablation of basivertebral nerves of the L3 through S1 vertebrae